Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People between 12 months and 39 years of age at the time of joining the screening process
- People who have been newly diagnosed with a high-grade brain tumour (including a type called DIPG), where the diagnosis has been confirmed through a biopsy or surgical removal of tumour tissue and reviewed by a pathologist at the treating hospital
- People diagnosed with DIPG must have a tumour centred in a specific part of the brainstem (the pons) that affects at least two-thirds of it, confirmed as a certain type of brain tumour under standard medical classification
- People with other high-grade brain tumours (not DIPG) must have a tumour classified as the most serious grades (WHO grade 3 or 4)
- People do not need to have a measurable tumour to be eligible
- People whose cancer has spread to other areas of the brain or spine, or who have tumours in multiple locations, may still be eligible
- People with a tumour starting in the spine may be eligible
- People whose high-grade brain tumour developed as a result of previous radiation treatment may be eligible
- People who have had surgery, radiation therapy, steroid medication (dexamethasone), or a specific chemotherapy (temozolomide given alongside radiation) before joining may be eligible
- People who have previously received a drug called bevacizumab (Avastin) may be eligible (confirm with trial site regarding timing requirements)
- People must be enrolled within specific timeframes relative to diagnosis and completion of radiation therapy, depending on which screening pathway is used (confirm with trial site for exact timing requirements)
- People must have tumour tissue available for molecular testing, or results from previous detailed tumour genetic testing, submitted according to the screening pathway being used
- A parent, legal guardian, or the patient themselves must be willing and able to sign a consent form; age-appropriate agreement from the patient will also be sought where suitable
Who may not be able to join:
- People whose tumour does not meet the specific definitions of high-grade brain tumour or DIPG described above
- People who have received any other cancer treatment (beyond surgery, radiation, dexamethasone, temozolomide with radiation, or bevacizumab) for their high-grade brain tumour
- People being considered for the lorlatinib treatment arm who have already received radiation therapy
- People whose radiation therapy began more than 42 days after their surgery or biopsy (confirm with trial site, as earlier start times are strongly recommended)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Maryam Fouladi, MD, Nationwide Children's Hospital
Phone: 16147223284
Australian sites
+61293821730
+61730683593
+61 3 9345 5479
+61864560241
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Molecular profiling; Feasibility of molecular profiling and enrollment to a TarGeT treatment protocol
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.